Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer

Jovanović, Dragana; Roksandić-Milenković, Marina; Kotur‐Stevuljević, Jelena; Ceriman, Vesna; Vukanić, Ivana; Samardžić, Natalija; Popević, Spasoje; Ilić, Branislav; Gajić, M; Șimon, Mărioara; Şimon, Ioan; Spasojević‐Kalimanovska, Vesna; Belić, Milica; Mirkov, D; Šumarac, Zorica; Milenković, Vladislav

doi:10.2478/jomb-2018-0036

Cited by 23 publications

(14 citation statements)

References 41 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Except for the expression of immune checkpoint molecules in the tissues, sPD-L1 detection also drew attention. Recently, research has shown that high sPD-L1 levels were proved as prognostic for poor treatment response and survival prognosis in hepatocellular carcinoma [ 34 ], renal cell cancer [ 35 ], ovarian cancer [ 36 ], lung cancer [ 37 ], gastric cancer [ 38 ], melanoma [ 39 ] and extranodal NK/T cell lymphoma [ 40 ]. To the best of our knowledge, the current work is the first to investigate the clinical prognostic complications of plasma sPD-L1 in recurrent or metastatic breast cancer patients before receiving first-line rescue therapy.…”

Section: Discussionmentioning

confidence: 99%

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte

Han

Dong

Zhou

et al. 2021

Cancer Immunol Immunother

View full text Add to dashboard Cite

This work investigated the clinical prognostic implications and biological function of plasma soluble programmed cell death ligand 1 in breast cancer patients. Plasma sPD-L1 levels of recurrent/metastatic breast cancer patients were determined, and the association of sPD-L1 levels and metastatic progression-free survival and metastatic overall survival was assessed. The PD-L1 expression on breast cancer cells was analyzed by flow cytometry, and the level of sPD-L1 in the supernatant of breast cancer cells was determined by enzyme-linked immunosorbent assay. Furthermore, the effect of sPD-L1 on the proliferation and apoptosis of T lymphocytes was detected by WST-1 assay and flow cytometry. The plasma sPD-L1 levels in 208 patients with recurrent/metastatic breast cancer before receiving first-line rescue therapy were measured. The optimal cutoff value of plasma sPD-L1 for predicting disease progression was 8.774 ng/ml. Univariate and multivariate analyses identified high sPD-L1 level (≥ 8.774 ng/ml) and visceral metastasis were independent factors associated with poor prognosis. Relevance analysis showed that the plasma sPD-L1 level was weaklyassociated with some systemic inflammation markers, including white cell count (WBC), absolute monocytecount, and absolute neutrophil count. Furthermore, we found sPD-L1 could be found in supernatant of culture with breast cancer cell line expressing PD-L1 on the cell surface and inhibit T lymphocyte function, playing a negative regulatory role in cellular immunity. sPD-L1 was a good tumor predictive maker in breast cancer and it may play a potentially important role in immune tolerance.

show abstract

Section: Discussionmentioning

confidence: 99%

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte

Han

Dong

Zhou

et al. 2021

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…However, unlike previous reports [ 24 , 39 ], serum sPD-L1 levels were not significantly associated with PD-L1 expression in the tissue samples in our analysis. Some studies reported sPD-L1 as a candidate serum biomarker [ 10 , 40 , 41 ]. Similarly, our findings showed that pretreatment sPD-L1 levels were higher in NPC patients than in control patients ( Figure 4 ).…”

Section: Discussionmentioning

confidence: 99%

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma

et al. 2021

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated malignancy. The principal oncogene of EBV, latent membrane protein 1 (LMP1), induces the expression of programmed death-ligand 1 (PD-L1), which is an immunosuppressive transmembrane protein and a promising therapeutic target for various malignancies. Recent studies have revealed an association between the level of soluble PD-L1 (sPD-L1) and disease progression. However, the role of sPD-L1 in NPC or its relevance to LMP1 has not been elucidated. This study aimed to examine whether LMP1 induces sPD-L1 in vitro and analyze the clinical relevance of LMP1, PD-L1, and sPD-L1 in NPC patients. Analysis of nasopharyngeal cell lines revealed that LMP1 induces both cellular PD-L1 and sPD-L1. Analysis of biopsy specimens from 32 NPC patients revealed that LMP1 expression was significantly correlated with PD-L1 expression. Finally, the serum sPD-L1 level in NPC patients was higher than that in the controls. Moreover, the sPD-L1 level in the advanced stage was higher than that in the early stage. However, LMP1 expression, PD-L1 expression, and sPD-L1 levels were not associated with prognosis. These results suggest that LMP1 induces both sPD-L1 and PD-L1, which are associated with NPC progression.

show abstract

“…However, systemic inflammation will depress cellular immunity, resulting in lymphocytopenia, which was marked as a decrease in CD4+ helper lymphocytes and an increase in CD8+ suppressor lymphocytes (17). In contrast, tumour-associated macrophages (TAMs) are circulating monocytes that are recruited to tumour sites in excess (18)(19).…”

Section: Discussionmentioning

confidence: 99%

Preoperative lymphocyte-to-monocyte ratio versus platelet-to-lymphocyte ratio as a prognostic predictor for non-small cell lung cancer patients

Yan¹,

Cai²,

Chen³

et al. 2019

Journal of Medical Biochemistry

View full text Add to dashboard Cite

Summary Background We investigated the prognostic value of the preoperative lymphocyte-to-mononuclear ratio (LMR) and platelet-to-lymphocyte ratio (PLR) in a large cohort of patients with non-small cell lung cancer (NSCLC). Methods Clinical-pathological data from 507 NSCLC patients at Taizhou Hospital of Zhejiang Province between 2010 and 2016 were retrospectively evaluated. X-tile software was used to assess the optimal cutoff levels for LMR and PLR. Univariate and multivariate Cox regression models were used to assess the prognostic factors. Results The median follow-up duration after surgical resection was 34.5 months. Patients were stratified into 2 groups by LMR (2.6 and = 2.6) and PLR (179.6 and = 179.6). Our results revealed that lower LMR (HR = 3.163 (1.821–5.493), P = 0.000), age (HR = 2.252 (1.412–3.592), P = 0.001), T stage (HR = 3.749 (2.275–6.179), P = 0.000), N stage (HR = 3.106 (1.967–4.902), P = 0.000), and cut edge (HR = 3.830 (1.077–13.618), P = 0.038) were considered to be independent indicators for overall survival (OS) of NSCLC patients. For disease-free survival (DFS), age, sex, T stage, N stage, LMR and cut edge were verified to be independent prognostic factors in patients with NSCLC. Conclusions In the study cohort, reduced LMR was a robust independent predictor for both OS and DFS in patients with NSCLC who underwent surgical resection.

show abstract

Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer

Cited by 23 publications

References 41 publications

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte

The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte

Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma

Preoperative lymphocyte-to-monocyte ratio versus platelet-to-lymphocyte ratio as a prognostic predictor for non-small cell lung cancer patients

Contact Info

Product

Resources

About